These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 8351755)
1. Platinum accumulation in the kidney and changes in creatinine clearance following chemotherapy with cisplatin in humans. Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Kamura T; Nakano H; Sueishi K Urol Int; 1993; 51(2):57-61. PubMed ID: 8351755 [TBL] [Abstract][Full Text] [Related]
2. Platinum accumulation in the kidney and liver following chemotherapy with cisplatin in humans. Uozumi J; Ueda T; Yasumasu T; Koikawa Y; Naito S; Kumazawa J; Sueishi K Int Urol Nephrol; 1993; 25(3):215-20. PubMed ID: 8225820 [TBL] [Abstract][Full Text] [Related]
3. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. Stewart DJ; Mikhael NZ; Nanji AA; Nair RC; Kacew S; Howard K; Hirte W; Maroun JA J Clin Oncol; 1985 Sep; 3(9):1251-6. PubMed ID: 4040958 [TBL] [Abstract][Full Text] [Related]
4. Renal handling of cis-diamminedichloroplatinum(II). Jacobs C; Kalman SM; Tretton M; Weiner MW Cancer Treat Rep; 1980; 64(12):1223-6. PubMed ID: 7193518 [TBL] [Abstract][Full Text] [Related]
5. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies]. Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315 [TBL] [Abstract][Full Text] [Related]
6. Time course of the binding of platinum to subfractions of the kidney cytosol in the cisplatin-treated rat. Mason R; Hogg S; Edwards IR Res Commun Chem Pathol Pharmacol; 1986 Apr; 52(1):51-8. PubMed ID: 3715197 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Vermorken JB; van der Vijgh WJ; Klein I; Gall HE; van Groeningen CJ; Hart GA; Pinedo HM Clin Pharmacol Ther; 1986 Feb; 39(2):136-44. PubMed ID: 3943271 [TBL] [Abstract][Full Text] [Related]
9. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Campbell AB; Kalman SM; Jacobs C Cancer Treat Rep; 1983 Feb; 67(2):169-72. PubMed ID: 6681731 [TBL] [Abstract][Full Text] [Related]
10. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation and apoptosis in the kidney. Domitrović R; Cvijanović O; Pugel EP; Zagorac GB; Mahmutefendić H; Škoda M Toxicology; 2013 Aug; 310():115-23. PubMed ID: 23770416 [TBL] [Abstract][Full Text] [Related]
11. Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy. Chang GC; Yang TY; Shih CM; Lin LY; Lee HS; Chiang CD J Formos Med Assoc; 2003 Apr; 102(4):257-61. PubMed ID: 12833190 [TBL] [Abstract][Full Text] [Related]
12. Tissue platinum after clinical treatment with cisplatin or carboplatin in tumor-bearing patients. Minami T; Tohno Y; Tohno S; Utsumi M; Yamada M; Hashii K; Tateyama I; Kadota E; Okazaki Y Biol Trace Elem Res; 1997; 58(1-2):77-83. PubMed ID: 9363322 [TBL] [Abstract][Full Text] [Related]
13. Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations. Nanji AA; Mikhael NZ; Stewart DJ Arch Intern Med; 1985 Nov; 145(11):2013-4. PubMed ID: 4062451 [TBL] [Abstract][Full Text] [Related]
14. Distribution of Pt in the urine and kidney of the cisplatin treated rat. Mason RW; Hogg SJ; Edwards IR Toxicology; 1986 Feb; 38(2):219-26. PubMed ID: 3945972 [TBL] [Abstract][Full Text] [Related]
15. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Boer H; Proost JH; Nuver J; Bunskoek S; Gietema JQ; Geubels BM; Altena R; Zwart N; Oosting SF; Vonk JM; Lefrandt JD; Uges DR; Meijer C; de Vries EG; Gietema JA Ann Oncol; 2015 Nov; 26(11):2305-10. PubMed ID: 26347114 [TBL] [Abstract][Full Text] [Related]
16. Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration. Stewart DJ; Dulberg C; Molepo JM; Mikhael NZ; Montpetit VA; Redmond MD; Goel R Cancer Chemother Pharmacol; 1994; 34(1):14-22. PubMed ID: 8174197 [TBL] [Abstract][Full Text] [Related]
17. Histopathological study of human cisplatin nephropathy. Tanaka H; Ishikawa E; Teshima S; Shimizu E Toxicol Pathol; 1986; 14(2):247-57. PubMed ID: 3764321 [TBL] [Abstract][Full Text] [Related]
18. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137 [TBL] [Abstract][Full Text] [Related]
19. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin. Funakoshi Y; Fujiwara Y; Kiyota N; Mukohara T; Shimada T; Toyoda M; Imamura Y; Chayahara N; Tomioka H; Umezu M; Otsuki N; Nibu K; Minami H Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871 [TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of cumulative very high dose of cisplatin in chemotherapy resistant solid tumors. Tebano MT; Carlini P; Loizzo A; Luzi M; Petrucci F; Alimonti A; Caroli S Ann Ist Super Sanita; 1995; 31(3):351-7. PubMed ID: 8712579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]